PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis

Xu,Xin; Xie,Yanqi; Lin,Yiwei; Xu,Xianglai; Zhu,Yi; Mao,Yeqing; Hu,Zhenghui; Wu,Jian; Chen,Hong; Zheng,Xiangyi; Qin,Jie; Xie,Liping

doi:10.3892/etm.2012.734

PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis

Authors:
- Xin Xu
- Yanqi Xie
- Yiwei Lin
- Xianglai Xu
- Yi Zhu
- Yeqing Mao
- Zhenghui Hu
- Jian Wu
- Hong Chen
- Xiangyi Zheng
- Jie Qin
- Liping Xie
View Affiliations

Affiliations: Department of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: October 2, 2012 https://doi.org/10.3892/etm.2012.734
Pages: 1127-1133

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Plasminogen activator inhibitor-1 (PAI-1), belonging to the urokinase plasminogen activation (uPA) system, is involved in cancer development and progression. The PAI-1 promoter 4G/5G polymorphism was shown to contribute to genetic susceptibility to cancer, although the results were inconsistent. To assess this relationship more precisely, a meta-analysis was performed. The electronic databases PubMed, Scopus, Web of Science and Chinese National Knowledge Infrastructure (CNKI) were searched; data were extracted and analyzed independently by two reviewers. Ultimately, 21 eligible case-control studies with a total of 8,415 cancer cases and 9,208 controls were included. The overall odds ratio (OR) with its 95% confidence interval (CI) showed a statistically significant association between the PAI-1 promoter 4G/5G polymorphism and cancer risk (4G/4G vs. 5G/5G: OR=1.25, 95% CI=1.07-1.47, Pheterogeneity=0.001; 4G/4G vs. 4G/5G+5G/5G: OR=1.10, 95% CI=1.03-1.17, Pheterogeneity=0.194; 4G/4G+4G/5G vs. 5G/5G: OR=1.17, 95% CI=1.01-1.35, Pheterogeneity=0.041). In further subgroup analyses, the increased risk of cancer was observed in a subgroup of Caucasians with regards to endometrial cancer. Our meta-analysis suggests that the PAI-1 4G/5G polymorphism most likely contributes to susceptibility to cancer, particularly in Caucasians. Furthermore, the 4G allele may be associated with an increased risk of endometrial cancer.

View Figures

View References

1	Sleeman J and Steeg PS: Cancer metastasis as a therapeutic target. Eur J Cancer. 46:1177–1180. 2010. View Article : Google Scholar : PubMed/NCBI
2	Dellas C and Loskutoff DJ: Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost. 93:631–640. 2005.PubMed/NCBI
3	Loktionov A, Watson MA, Stebbings WS, Speakman CT and Bingham SA: Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis. Cancer Lett. 189:189–196. 2003. View Article : Google Scholar : PubMed/NCBI
4	Harbeck N, Kates RE, Look MP, et al: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res. 62:4617–4622. 2002.PubMed/NCBI
5	Pappot H, Pedersen AN, Brunner N and Christensen IJ: The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis. Lung Cancer. 51:193–200. 2006. View Article : Google Scholar
6	Sakakibara T, Hibi K, Koike M, et al: Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer. Cancer Sci. 97:395–399. 2006. View Article : Google Scholar : PubMed/NCBI
7	Schmitt M, Mengele K, Napieralski R, et al: Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn. 10:1051–1067. 2010. View Article : Google Scholar : PubMed/NCBI
8	Ny T, Sawdey M, Lawrence D, Millan JL and Loskutoff DJ: Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA. 83:6776–6780. 1986. View Article : Google Scholar : PubMed/NCBI
9	Kohler HP and Grant PJ: Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 342:1792–1801. 2000. View Article : Google Scholar : PubMed/NCBI
10	Anvari A, Schuster E, Gottsauner-Wolf M, Wojta J and Huber K: PAI-I 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease. Thromb Res. 103:103–107. 2001. View Article : Google Scholar : PubMed/NCBI
11	Grancha S, Estelles A, Tormo G, et al: Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost. 81:516–521. 1999.PubMed/NCBI
12	Blasiak J and Smolarz B: Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer. Acta Biochim Pol. 47:191–199. 2000.PubMed/NCBI
13	Castelló R, España F, Vázquez C, et al: Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res. 117:487–492. 2006.PubMed/NCBI
14	Eroglu A, Ulu A, Cam R and Akar N: Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer. J BUON. 11:481–484. 2006.PubMed/NCBI
15	Sternlicht MD, Dunning AM, Moore DH, et al: Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev. 15:2107–2114. 2006. View Article : Google Scholar
16	Lei H, Hemminki K, Johansson R, et al: PAI-1-675 4G/5G polymorphism as a prognostic biomarker in breast cancer. Breast Cancer Res Treat. 109:165–175. 2008. View Article : Google Scholar : PubMed/NCBI
17	Palmirotta R, Ferroni P, Savonarola A, et al: Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res. 124:403–408. 2009. View Article : Google Scholar : PubMed/NCBI
18	Försti A, Lei H, Tavelin B, et al: Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer. Ann Oncol. 18:1990–1994. 2007.PubMed/NCBI
19	Woo M, Park K, Nam J and Kim JC: Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol. 22:1064–1070. 2007. View Article : Google Scholar : PubMed/NCBI
20	Vossen CY, Hoffmeister M, Chang-Claude JC, Rosendaal FR and Brenner H: Clotting factor gene polymorphisms and colorectal cancer risk. J Clin Oncol. 29:1722–1727. 2011. View Article : Google Scholar : PubMed/NCBI
21	Türkmen B, Schmitt M, Schmalfeldt B, et al: Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer. Electrophoresis. 18:686–689. 1997.PubMed/NCBI
22	Bentov Y, Brown TJ, Akbari MR, et al: Polymorphic variation of genes in the fibrinolytic system and the risk of ovarian cancer. PLoS One. 4:e59182009. View Article : Google Scholar : PubMed/NCBI
23	Vairaktaris E, Yapijakis C, Serefoglou Z, et al: Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer. Oral Oncol. 42:888–892. 2006. View Article : Google Scholar : PubMed/NCBI
24	Weng CJ, Lin CW, Chung TT, Tsai CM, Chen MK and Yang SF: Impact of uPA system gene polymorphisms on the susceptibility of environmental factors to carcinogenesis and the development of clinicopathology of oral cancer. Ann Surg Oncol. 18:805–812. 2011. View Article : Google Scholar : PubMed/NCBI
25	Gilabert-Estelles J, Ramon LA, Braza-Boils A, et al: Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity. Thromb Res. 130:242–247. 2011. View Article : Google Scholar : PubMed/NCBI
26	Su CK, Yeh KT, Yeh CB, et al: Genetic polymorphism of the plasminogen activator inhibitor-1 is associated with an increased risk of endometrial cancer. J Surg Oncol. 104:755–759. 2011. View Article : Google Scholar : PubMed/NCBI
27	Ju H, Lim B, Kim M, et al: SERPINE1 intron polymorphisms affecting gene expression are associated with diffuse-type gastric cancer susceptibility. Cancer. 116:4248–4255. 2010. View Article : Google Scholar : PubMed/NCBI
28	Weng CJ, Tsai CM, Chen YC, et al: Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol. 17:3394–3401. 2010. View Article : Google Scholar : PubMed/NCBI
29	Wells GA, Shea B, O’Connell D, et al: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Health Research Institute. http://www.ohri.ca/programs/clinical_epidemiology/oxford.aspuri. 2011, Accessed March 14, 2012.
30	DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials. 7:177–188. 1986. View Article : Google Scholar : PubMed/NCBI
31	Mantel N and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
32	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
33	Eroglu A, Ulu A, Cam R and Akar N: Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients. J BUON. 12:135–136. 2007.PubMed/NCBI
34	Zhou X and Xia SH: The study of the PAI-1 activity and its promoter region polymorphism in ovarian cancer. Guizhou Medical Journal. 29:1072–1075. 2005.
35	Bi YT, Zheng M and Liang WD: The correlation between 4G/5G polymorphism located in the promoter region of PAI-I gene and breast cancer. Chinese Journal of Birth Health & Heredity. 12:26–27. 2004.
36	Eriksson P, Kallin B, van ‘t Hooft FM, Bavenholm P and Hamsten A: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 92:1851–1855. 1995. View Article : Google Scholar : PubMed/NCBI
37	Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T and Kanetake H: Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. J Urol. 174:461–465. 2005. View Article : Google Scholar
38	Swiatkowska M, Szemraj J and Cierniewski CS: Induction of PAI-1 expression by tumor necrosis factor alpha in endothelial cells is mediated by its responsive element located in the 4G/5G site. FEBS J. 272:5821–5831. 2005. View Article : Google Scholar : PubMed/NCBI
39	Chen YQ, Sloan-Lancaster J, Berg DT, Richardson MA, Grinnell B and Tseng-Crank J: Differential mechanisms of plasminogen activator inhibitor-1 gene activation by transforming growth factor-beta and tumor necrosis factor-alpha in endothelial cells. Thromb Haemost. 86:1563–1572. 2001.